4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immutep Limited (IMMP) operates in the Biotechnology industry and is headquartered in Sydney, Australia. Its market capitalization is roughly $54 million. In the fiscal year ended 2026-06-30, IMMP reported AUD 15M in revenue and (AUD 79M) in net income.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Interactive charts & full statements → Open the IMMP valuation workbench →
| Income statement | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue | AUD 15M | — | AUD 0M | AUD 0M | AUD 0M |
| Operating Income (EBIT) | (AUD 82M) | — | (AUD 47M) | (AUD 41M) | (AUD 34M) |
| Net Income | (AUD 79M) | — | (AUD 43M) | (AUD 40M) | (AUD 32M) |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | — | AUD 0M | AUD 0M | — | — |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets | AUD 83M | — | AUD 202M | AUD 147M | AUD 102M |
| Total Liabilities | AUD 22M | — | AUD 12M | AUD 11M | AUD 8M |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMMP viewer.
About TickerBase · Data methodology & sources · Privacy · Terms